Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET Imaging of Inflammation and Lipid Lowering Study
NCT04073797Completed
- Sponsor
- University of Cambridge
- Start
- Mar 2023
- Primary completion
- May 2026
- Modality
- Antisense DNA, Nucleic Acid-Directed Small Molecules, Conjugated siRNA
- Countries
- 1
01
Overview
Randomised, double-blind trial of inclisiran and colchicine in hypercholesterolemia, cardiovascular disease (CVD) and atherosclerosis (3 arms), sponsored by University of Cambridge. Primary endpoints: Carotid 68Ga-DOTATATE Positron Emission Tomography at 12 weeks and Carotid Ultrasound Plaque Structure Analysis imaging at 12 weeks. Started Mar 2023; status: completed.
02
Drugs
inclisirancolchicine
03
Conditions
hypercholesterolemiacardiovascular disease (CVD)atherosclerosis
Beyond the preview
Go deeper on NCT04073797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04073797.